Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Sundström, H.
Right arrow Articles by Kauppila, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sundström, H.
Right arrow Articles by Kauppila, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1984 Oxford University Press

other

Serum selenium in patients with ovarian cancer during and after therapy

Helena Sundström 1 2, Erkki Yrjänheikki 3 and Antti Kauppila 1

1Department of Obstetrics and Gynaecology, University of Oulu SF-90220 Oulu, Finland
3Oulu Regional Institute of Occupational Health SF-90220 Oulu, Finland

Serum concentrations of selenium were determined by atomic absorption spectrophotometry in 40 patients with ovarian cancer in association with and after surgical and cytostatic therapy. Patients with ovarian cancer had significantly (p <0.001) lower serum concentrations (mean±SE) of selenium (0.93 ±0.04 µmol/1) than age-, weight- and place of residence-matched control subjects (1.22 ±0.03 µmol/1). In clinical stage IV disease there was a lower serum level of selenium (0.82 ±0.07 µmol/1) than in clinical stages I and II combined (1.00±0.04 µmol/l). Serum selenium concentrations also showed a tendency to follow the outcome of the disease; an increase in patients with remission and a decrease in patients with progressive disease, probably because of nutritional reasons.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
K. W. Last, A. Z.S. Rohatiner, J. Fitzgibbon, and T. A. Lister
In Reply:
J. Clin. Oncol., August 15, 2004; 22(16): 3430 - 3430.
[Full Text] [PDF]

Home page
 JCOHome page
E. J. Ladas, J. S. Jacobson, D. D. Kennedy, K. Teel, A. Fleischauer, and K. M. Kelly
Antioxidants and Cancer Therapy: A Systematic Review
J. Clin. Oncol., February 1, 2004; 22(3): 517 - 528.
[Abstract] [Full Text] [PDF]

Home page
 International Journal of ToxicologyHome page
W.C. Willett and M.J. Stampfer
Selenium and Human Cancer: Epidemiological Aspects and Implications for Clinical Trials
International Journal of Toxicology, January 1, 1986; 5(1): 29 - 36.
[PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.